Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
LG is getting into phase III trial of biosimilar Enbrel
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Dec 29, 2014 07:26:52
LG Life Sciences plans to conduct a phase III clinical trial for LBEC0101 its biosimilar of Enbrel as the Ministry of Food and Drug Safety approved LG’s protocol on December 23.

LG started working on LBEC0101 in 2010. It failed the phase I clinical trial at first, so it conducted the same trial again two years later in 2012 and completed it finally.

Now it will compare LBEC0101 with Enbrel when co-administered with methotrexate. The clinical trial will be conducted in Seoul National University Medical Center, South Korea and a medical center in Japan.

LG expects it will be able to commercialize LBEC0101 in 2-3 years. Samsung and Daewoong are also developing their biosimilar of Enbrel and Hanwha recently got marketing approval for its biosimilar.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com